Company Information
Industry 制造业
Company Introduction 石家庄以岭药业股份有限公司于1992年6月16日创建(股票代码002603),公司以“继承创新、造福人类”为企业宗旨,“科技健康明天”为发展目标,“为员工谋发展,对社会做贡献,为股东创价值”为经营理念,始终坚持科技先导、市场龙头的创新发展战略,首次系统构建了络病理论体系,创立了“理论-临床-科研-产业-教学”五位一体的运营模式,形成了“从医到药到健康”的产业发展集群,“中医络病诊疗方法”列入了国家级非物质文化遗产,《络病学》成为大学教材,在全国40余所高校开课。先后承担国家973、国家863、国家自然科学基金、国家重点研发计划等国家级、省部级课题60余项。公司研发治疗冠心病、脑梗塞的通心络胶囊,快慢兼治心律失常的参松养心胶囊,标本兼治慢性心衰的芪苈强心胶囊,治感冒、抗流感的连花清瘟胶囊,补肾精、抗衰老的八子补肾胶囊等专利新药10余个,获得专利800余项,荣获国家科技进步一等奖、国家科技进步二等奖等六项国家大奖。在河北和北京等地建设了5个生产研发基地,在全国建立了30余个中药材原材料基地,生产车间先后通过了美国、欧盟、加拿大、新西兰等多个国家和地区的国际认证,建立了符合国际标准的全面质量控制体系。连花清瘟在30余个国家上市。公司为中国中药10强企业、中国医药上市20强企业、中国上市公司市值500强企业、中国品牌价值100强企业,被中共中央授予“全国先进基层党组织”称号。
Main Business 药品的研发、生产和销售。
Legal Representative 吴相君
Top Executives
董事长:吴相君
名誉董事长:吴以岭
董事:赵韶华,张秋莲,徐卫东,李晨光,吴瑞,吴相君
独立董事:柴振国,陈刚,刘骁悍
Top 5 Shareholder
Shareholder name Nature Holding Date
以岭医药科技有限公司流通A股31.53%30/09/2024
吴相君限售股+流通A股20.81%30/09/2024
吴瑞限售股+流通A股2.34%30/09/2024
香港中央结算有限公司流通A股1.89%30/09/2024
田书彦流通A股1.42%30/09/2024
Company Secretary 吴瑞
Solicitors 北京国枫律师事务所
Auditors 中勤万信会计师事务所(特殊普通合伙)
Tel No 0311-85901311
Fax No 0311-85901311
Website www.yiling.cn
Email 002603@yiling.cn;wang.hua@yiling.cn
Company Address
Register: 河北省石家庄市高新技术产业开发区天山大街238号
Office: 河北省石家庄市高新技术产业开发区天山大街238号
Listing Date 28/07/2011
Shares Capital
Shares Capital: 1,670,705,376
Total A Share: 1,670,705,376
Listed A Share: 1,376,309,487
Non-tradable A Share: 294,395,889
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.810
DPS(RMB)* ¥ 0.300
NBV Per Share(RMB)* ¥ 6.853
Market Capitalization(RMB) 19.901B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.